Rasool Roohi, Shera Irfan Ali, Nissar Saniya, Shah Zaffar A, Nayak Niyaz, Siddiqi Mushtaq A, Sameer Aga Syed
Department of Immunology and Molecular Medicine, Sher-I-Kashmir Institute of Medical Sciences, Soura, Srinagar, Kashmir, India.
Indian J Dermatol. 2013 Jan;58(1):12-7. doi: 10.4103/0019-5154.105276.
Skin prick test (SPT) is the most effective diagnostic test to detect IgE mediated type I allergic reactions like allergic rhinitis, atopic asthma, acute urticaria, food allergy etc. SPTs are done to know allergic sensitivity and applied for devising immunotherapy as the therapeutic modality.
This prospective study was conducted in the department of Immunology and Molecular medicine at SKIMS. A total of 400 patients suffering from allergic rhinitis, asthma and urticaria were recruited in this study. SPT was performed with panel of allergens including house dust mite, pollens, fungi, dusts, cockroach, sheep wool and dog epithelia. Allergen immunotherapy was given to allergic rhinitis and asthmatic patients as therapeutic modality.
In our study, age of patients ranged from 6 to 65 years. Majority of patients were in the age group of 20-30 years (72%) with Male to female ratio of 1:1.5. Of the 400 patients, 248 (62%) had urticaria, 108 (27%) patients had allergic rhinitis and 44 (11%) patients had asthma. SPT reaction was positive in 38 (86.4%) with allergic asthma, 74 (68.5%) patients with allergic rhinitis and 4 (1.6%) patient with urticaria, respectively. Allergen immunotherapy was effective in 58% patients with allergic rhinitis and 42% allergic asthma.
Identifiable aeroallergen could be detected in 86.4% allergic asthma and 68.5% allergic rhinitis patients by SPT alone. Pollens were the most prevalent causative allergen. There was significant relief in the severity of symptoms, medication intake with the help of allergen immunotherapy.
皮肤点刺试验(SPT)是检测IgE介导的I型过敏反应(如过敏性鼻炎、特应性哮喘、急性荨麻疹、食物过敏等)最有效的诊断试验。进行SPT以了解过敏敏感性,并将其应用于设计免疫疗法作为治疗方式。
本前瞻性研究在SKIMS的免疫学与分子医学系进行。本研究共招募了400例患有过敏性鼻炎、哮喘和荨麻疹的患者。使用包括屋尘螨、花粉、真菌、灰尘、蟑螂、羊毛和狗上皮细胞在内的一组变应原进行SPT。对过敏性鼻炎和哮喘患者给予变应原免疫疗法作为治疗方式。
在我们的研究中,患者年龄范围为6至65岁。大多数患者年龄在20至30岁之间(72%),男女比例为1:1.5。在400例患者中,248例(62%)患有荨麻疹,108例(27%)患有过敏性鼻炎,44例(11%)患有哮喘。SPT反应在过敏性哮喘患者中38例(86.4%)呈阳性,在过敏性鼻炎患者中74例(68.5%)呈阳性,在荨麻疹患者中4例(1.6%)呈阳性。变应原免疫疗法在58%的过敏性鼻炎患者和42%的过敏性哮喘患者中有效。
仅通过SPT就能在86.4%的过敏性哮喘患者和68.5%的过敏性鼻炎患者中检测到可识别的空气变应原。花粉是最常见的致病变应原。在变应原免疫疗法的帮助下,症状严重程度和药物摄入量有显著缓解。